Evidence map›Paper›PMID 41379644›Full record

ArticleEmerging infectious diseases2025

Borrelia afzelii Hepatitis in Patient Treated with Venetoclax and Obinutuzumab, Switzerland.

Gioele Capoferri, Raphael Battegay, Baptiste Hamelin, Peter M Keller, Kirsten D Mertz, Maja Weisser

Abstract readCase Reports
In one paragraph

Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gioele Capoferri
Raphael Battegay
Baptiste Hamelin
Peter M Keller
Kirsten D Mertz
Maja Weisser

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report Borrelia afzelii hepatitis in an immunosuppressed patient in Switzerland receiving anti-CD20 therapy and venetoclax. Diagnosis was made by metagenomic sequencing and PCR. This case underscores the need to consider Lyme borreliosis in unexplained hepatitis cases and highlights the value of molecular diagnostics in immunosuppressed patients when serologic test results are negative.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsBorrelia burgdorferi GroupBridged Bicyclo Compounds, HeterocyclicHepatitisLyme DiseaseSulfonamidesHumansImmunocompromised HostSwitzerlandAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicobinutuzumabSulfonamidesvenetoclaxbacteriaBorrelia afzeliihepatitisimmunosuppressionLyme borreliosismolecular diagnosticsvector-borne infections

Identifiers

PMID41379644
PMCPMC12704518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.